FindTrial
Sign In

Finerenone Placebo

DRUG3 trials

Sponsors

Bayer, Juntendo University, Huijie Zhang

Conditions

Acute Heart FailureChronic Kidney DiseaseType 2 Diabetes MellitusType 2 Diabetic Kidney Disease

Phase 2

A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes
CompletedNCT05254002
BayerType 2 Diabetes Mellitus, Chronic Kidney Disease
Start: 2022-06-23End: 2025-03-17Updated: 2026-07-13

Phase 4

Efficacy and Safety With Early Treatment of Finerenone in Hospitalized Patients With Heart Failure
RecruitingNCT07397650
Juntendo UniversityAcute Heart Failure
Start: 2026-05-11End: 2028-09-30Target: 550Updated: 2026-08-10
QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy
Not yet recruitingNCT07775846
Huijie ZhangType 2 Diabetic Kidney Disease
Start: 2026-09-01End: 2029-06-30Target: 820Updated: 2026-08-20

Related Papers

Safety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure.
2026-06-05
Acute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone
Journal of the American Society of Nephrology2026-03-29
Sexual Dimorphism and Age Effects in CKD and Type 2 Diabetes in the CONFIDENCE Trial
Nephrology Dialysis Transplantation2026-03-27
Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial.
UNC Libraries2026-01-06
Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial.
2025-12-011 citations
Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized Trial.
2025-11-071 citations
Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both
Journal of the American Society of Nephrology2025-11-06
COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics.
2025-08-019 citations
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
New England Journal of Medicine2025-06-05117 citations
The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial
Nephrology Dialysis Transplantation2024-11-1232 citations
Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure
Circulation2024-09-2839 citations
Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial
Nephrology Dialysis Transplantation2024-06-1159 citations
Rationale and design of an investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized trial to evaluate the effects of finerenone on vascular stiffness and cardiorenal biomarkers in type 2 diabetes and chronic kidney disease (FIVE-STAR).
2023-07-316 citations
Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)
Nephrology Dialysis Transplantation2022-06-14148 citations